Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SARCLISA vs ARZERRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isatuximab is a monoclonal antibody that binds to CD38 on multiple myeloma cells, inducing apoptosis through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). It also inhibits CD38 enzymatic activity.
Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.
Treatment of multiple myeloma in combination with pomalidomide and dexamethasone in adults who have received at least two prior therapies including lenalidomide and a proteasome inhibitor,Treatment of multiple myeloma in combination with carfilzomib and dexamethasone in adults with relapsed or refractory multiple myeloma after 1-3 prior lines of therapy
Treatment of chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab,Treatment of previously untreated CLL in combination with chlorambucil,Treatment of relapsed CLL in combination with fludarabine and cyclophosphamide
10 mg/kg intravenously weekly for the first 8 weeks, then every 2 weeks thereafter until disease progression or unacceptable toxicity.
ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.
Terminal elimination half-life: 9-14 days (approx. 4 weeks to reach steady state in multiple dosing).
Mean terminal elimination half-life after first dose is approximately 14 days (range 7–21 days) and increases with repeated dosing due to target-mediated clearance saturation; at steady state, half-life is ~24 days.
Isatuximab is a monoclonal antibody, expected to be degraded into small peptides and amino acids via catabolic pathways. Not metabolized by CYP450 enzymes.
Ofatumumab is a monoclonal antibody; metabolism is not through typical cytochrome P450 pathways. Clearance involves catabolism to peptides and amino acids.
Renal: ~25% unchanged; Biliary/fecal: minor, primarily metabolized via liver, with metabolites excreted in bile/feces.
Arzerra (ofatumumab) is eliminated primarily via the reticuloendothelial system and catabolism; renal excretion is minimal (<1% of dose as intact antibody). Biliary/fecal excretion has not been characterized, but as a monoclonal antibody, it is not significantly excreted in urine or feces.
~70% bound to plasma proteins (primarily albumin and beta-2 glycoprotein I/apoferritin).
As a monoclonal antibody, ofatumumab does not bind to plasma proteins; protein binding is negligible.
Vd: 0.09 L/kg (approx. 6 L), consistent with limited extravascular distribution.
Volume of distribution (Vd) is approximately 2.5–4.5 L, approximating plasma volume; does not distribute extensively into tissues (not reported in L/kg, but typical for Ig G1 monoclonal antibodies ~0.1–0.2 L/kg).
IV only; bioavailability 100% by IV route. Not administered orally.
Subcutaneous: ~60–70% absolute bioavailability; intravenous: 100%.
No dose adjustment required for renal impairment (Cr Cl ≥15 m L/min). Not studied in end-stage renal disease (Cr Cl <15 m L/min) or dialysis; use caution.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or hemodialysis; use with caution.
No dose adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C); use with caution.
Safety and efficacy not established in pediatric patients. No recommended dose.
Safety and efficacy in pediatric patients (<18 years) have not been established; no recommended dosing.
No specific dose adjustment required. Consider comorbidities and renal function, but pharmacokinetics are similar to younger adults.
No specific dose adjustment required for elderly patients. Clinical studies included patients ≥65 years; overall efficacy and safety similar to younger adults, but higher incidence of serious infections and cardiac events observed.
No FDA black box warning.
Hepatitis B virus (HBV) reactivation can occur with ofatumumab, leading to fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before initiation. Monitor HBV carriers during and after treatment.
Infusion-related reactions (may require premedication and monitoring),Neutropenia (monitor complete blood counts),Thrombocytopenia,Second primary malignancies,Interference with blood cross-matching (due to CD38 binding),Embryofetal toxicity
Infusion reactions (including anaphylaxis), prolonged cytopenias, progressive multifocal leukoencephalopathy (PML), intestinal obstruction, tumor lysis syndrome, and infections including hepatitis B reactivation.
None known.
Known hypersensitivity (anaphylaxis) to ofatumumab or any of its excipients.
No specific food interactions. Avoid grapefruit juice if taking concurrent CYP3A4 substrates (e.g., pomalidomide) due to potential interaction. Maintain adequate hydration.
No known food interactions. Take with or without food.
First trimester: Ig G1 monoclonal antibodies cross placenta minimally; limited human data, but based on mechanism (CD38 inhibition), potential fetal hematologic effects. Second/third trimesters: Increased placental transfer; risk of fetal cytopenias and immune suppression.
ARZERRA (ofatumumab) is a human monoclonal antibody. Ig G molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), there is a potential risk of fetal B-cell lymphocytopenia and impaired immune response. Data from animal studies are insufficient. The drug should be avoided during pregnancy unless the benefit clearly outweighs the risk.
No data on human milk excretion; M/P ratio unknown. Human Ig G enters breast milk, but degradation in infant GI tract likely limits absorption. Weigh benefits of breastfeeding against potential infant exposure.
It is unknown whether ofatumumab is excreted in human milk. Human Ig G is present in breast milk, but levels are low. Due to the potential for serious adverse reactions in the breastfed infant (including B-cell depletion), breastfeeding is not recommended during therapy and for at least 6 months after the last dose. No M/P ratio is available.
No PK studies in pregnancy; dose adjustments not established. Isatuximab clearance may increase due to expanded plasma volume and altered Fc Rn activity, but no data to recommend specific changes. Use only if benefit outweighs risk.
No specific dose adjustment guidelines are established for pregnancy. The pharmacokinetics of monoclonal antibodies may be altered due to increased plasma volume and clearance in pregnancy, but no formal studies have been conducted. Use caution and consider therapeutic drug monitoring if available.
SARCLISA (isatuximab) is an anti-CD38 monoclonal antibody for multiple myeloma. Premedicate with acetaminophen, H1 and H2 antagonists, and corticosteroids before infusion to reduce infusion-related reactions. Administer pomalidomide and dexamethasone concurrently as per protocol. Monitor for neutropenia, infusion reactions, and second primary malignancies. Do not substitute for other anti-CD38 antibodies.
ARZERRA (ofatumumab) is a monoclonal antibody targeting CD20 used in relapsing multiple sclerosis. First dose reactions are common; premedicate with corticosteroids, antihistamines, and antipyretics. Monitor for infections, especially hepatitis B reactivation. Contraindicated in active hepatitis B. Administer as subcutaneous injection; injection site reactions frequent. Live vaccines contraindicated during and after treatment until immune reconstitution.
Infusion reactions: symptoms like fever, chills, rash, or difficulty breathing may occur during or after infusion; seek immediate medical attention.,Blood cell counts: this drug can decrease white blood cells, red blood cells, and platelets; report signs of infection, anemia, or bleeding.,Fetal harm: effective contraception required during and for 5 months after treatment; do not breastfeed.,Vaccinations: avoid live vaccines during treatment.,Laboratory interference: isatuximab may interfere with blood compatibility testing; inform all healthcare providers of treatment.
Report any signs of infection (fever, chills, cough, painful urination) promptly.,Inform your doctor of any history of hepatitis B infection.,You will receive premedication before the first dose to reduce allergic reactions.,Do not receive live vaccines during treatment or until your doctor confirms immune recovery.,Common side effects include injection site reactions, headache, and fever.,ARZERRA is given as an injection under the skin; rotation of injection sites is recommended.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SARCLISA vs ARZERRA, answered by our medical review team.
SARCLISA is a Monoclonal Antibody, Antineoplastic that works by Isatuximab is a monoclonal antibody that binds to CD38 on multiple myeloma cells, inducing apoptosis through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). It also inhibits CD38 enzymatic activity.. ARZERRA is a Antineoplastic, Monoclonal Antibody that works by Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SARCLISA and ARZERRA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SARCLISA is: 10 mg/kg intravenously weekly for the first 8 weeks, then every 2 weeks thereafter until disease progression or unacceptable toxicity.. The standard adult dose of ARZERRA is: ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SARCLISA and ARZERRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SARCLISA is classified as Category C. First trimester: IgG1 monoclonal antibodies cross placenta minimally; limited human data, but based on mechanism (CD38 inhibition), potential fetal hematologic effects. Second/thir. ARZERRA is classified as Category C. ARZERRA (ofatumumab) is a human monoclonal antibody. IgG molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.